Huntingtin DNA, protein and uses thereof

Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.

Description: Field of the Invention The invention is in the field of the detection and treatment of genetic diseases. Specifically, the invention is directed to the huntingtin gene (also called the IT15 gene), huntingtin protein encoded by such gene, and the use of this gene and protein in assays (1) for the detection of a predisposition to develop Huntington's disease, (2) for the diagnosis of Huntington's disease (3) for the treatment of Huntington's disease, and (4) for monitoring the course of treatment of such treatment. Background of the Invention Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor disturbance, cognitive loss and psychiatric manifestations (Martin and Gusella, N. Engl. J. Med. 315 :1267-1276 (1986). It is inherited in an autosomal dominant fashion, and affects about 1/10,000 individuals in most populations of European origin (Harper, P.S. et al ., in Huntington's disease, W.B. Saunders, Philadelphia, 1991). The hallmark of HD is a distinctive choreic movement disorder that typically has a subtle, insidious onset in the fourth to fifth decade of life and gradually worsens over a course of 10 to 20 years until death. Occasionally, HD is expressed in juveniles typically manifesting with more severe symptoms including rigidity and a more rapid course. Juvenile onset of HD is associated with a preponderance of paternal transmission of the disease allele. The neuropathology of HD also displays a distinctive pattern, with selective loss of neurons that is most severe in the caudate and putamen regions of the brain. The biochemical basis for neuronal death in HD has not yet been explained, and there is consequently no treatment effective in delaying or preventing the onset and progression of this devastating disorder. The genetic defect causing HD was assigned to chromosome 4 in 1983 in one of the first successes of linkage analysis using polymorphic DNA markers in man (Gusella et al., Nature 306 :234-238 (1983). Since that time, we have pursued a location cloning approach to isolating and characterizing the HD gene based on progressively refining its localization (Gusella, FASEB J. 3 :2036-2041 (1989); Gusella, Adv. Hum. Genet. 20 :125-151 (1991)). Among other work, this has involved the generation of new genetic markers in the region by a number of techniques (Pohl et al., Nucleic Acids Res. 16 :9185-9198 (1988); Whaley et al., Somat. Cell. Mol. Genet. 17 :83-91 (1991); MacDonald et al., J. Clin. Inv. 84 :1013-1016 (1989)), the establishment of genetic (MacDonald et al., Neuron 3 :183-190(1989); Allitto et al., Genomics 9 :104-112 (1991)) and physical maps of the implicated regions (Bucan et al., Genomics 6 :1-15 (1990); Bates et al., Nature Genet. 1 :180-187 (1992); Doucette-Stamm et al., Somat. Cell Mol. Genet. 17 :471-480 (1991); Altherr et al., Genomics 13 :1040-1046 (1992)), the cloning of the 4p telomere of an HD chromosome in a YAC clone (Bates et al., Am. J. Hum. Genet. 46 :762-775 (1990); Youngman et al., Genomics 14 :350-356 (1992)), the establishment of YAC [yeast artificial chromosome] (Bates et al., Nature Genet. 1 :180-187 (1992)) and cosmid (Baxendale et al., in preparation) contigs (a series of overlapping clones which together form a whole sequence) of the candidate region, as well as the analysis and characterization of a number of candidate genes from the region (Thompson et al., Genomics 11 :1133-1142 (1991); Taylor et al., Nature Genet. 2 :223-227 (1992); Ambrose et al., Hum. Mol. Genet. 1 :697-703 (1992)). Analysis of recombination events in HD kindreds has identified a candidate region of 2.2 Mb, between D4S10 and D4S98 in 4p16.3, as the most likely position of the HD gene (MacDonald et al., Neuron 3 :183-190 (1989); Bates et al., Am. J. Hum. Genet. 49 :7-16 (1991); Snell et al., Am. J. Hum. Genet. 51 :357-362 (1992)). Investigations of linkage disequilibrium between HD and DNA markers in 4p16.3 (Snell et al. , J. Med. Genet. 26 :673-675 (1989); Theilman et al., J. Med. Genet. 26 :676-681 (1989)) have suggested that multiple mutations have occurred to cause the disorder (MacDonald et al., Am. J. Hum. Genet. 49 :723-734 (1991)). However, haplotype analysis using multi-allele markers has indicated that at least 1/3 of HD chromosomes are ancestrally related (MacDonald et al., Nature Genet. 1: 99-103 (1992)). The haplotype shared by these HD chromosomes points to a 500 kb segment between D4S180 and D4S182 as the most likely site of the genetic defect. Targeting this 500 kb region for saturation with gene transcripts, exon amplification has been used as a rapid method for obtaining candidate coding sequences (Buckler et al., Proc. Natl. Acad. Sci. USA 88 :4005-4009 (1991)). This strategy has previously identified three genes: the a-adducin gene (ADDA) (Taylor et al., Nature Genet. 2 :223-227 (1992)); a putative novel transporter gene (IT10C3) in the distal portion of this segment; and a novel G protein-coupled receptor kinase gene (IT11) in the central portion (Ambrose et al. , Hum. Mol. Genet. 1 :697-703 (1992)). However, no defects implicating any of these genes as the HD locus have been found. Summary of the Invention A large gene, termed herein "huntingtin" or "IT15," has been identified that spans about 210 kb and encodes a previously undescribed protein of about 348 kDa. The huntingtin reading frame contains a polymorphic (CAG) n trinucleotide repeat with at least 17 alleles in the normal population, varying from 11 to about 34 CAG copies. On HD chromosomes, the length of the trinucleotide repeat is substantially increased, for example about 37 to at least 73 copies, and shows an apparent correlation with age of onset, the longest segments are detected in juvenile HD cases. The instability in length of the repeat is reminiscent of similar trinucleotide repeats in the fragile X syndrome and in myotonic dystrophy (Suthers et al., J. Med. Genet. 29:761-765 (1992)). The presence of an unstable, expandable trinucleotide repeat on HD chromosomes in the region of strongest linkage disequilibrium with the disorder suggests that this alteration underlies the dominant phenotype of HD, and that huntingtin encodes the HD gene. The invention is directed to the protein huntingtin, DNA and RNA encoding this protein, and uses thereof. According to a first aspect of the present invention, there is provided an isolated, purified or recombinant huntingtin polypeptide comprising the amino acid sequence shown in SEQ ID NO:6. According to a second aspect of the present invention, there is provided an isolated, purified or recombinant nucleic acid molecule comprising a huntingtin nucleic acid molecule encoding a huntingtin polypeptide in accordance with the first aspect of the invention, or its complementary strand. Preferably, the nucleic acid molecule comprises the nucleic acid shown in SEQ ID NO:5, and may comprise a transcriptional control region operably linked to the huntingtin nucleic acid molecule. The invention also provides, in a third aspect, a vector comprising a nucleic acid molecule of the second aspect of the invention. In this vector, the nucleic acid molecule may be operably linked to transcriptional and/or translational expression signals. In a fourth aspect, the invention provides a host cell transformed or transfected with a vector according to the third aspect of the invention. In fifth and sixth aspects, the invention also provides an antibody specific for huntingtin polypeptide of the first aspect, and a hybridoma which produces such an antibody. According to a seventh aspect, the invention provides a method of detecting the presence of, or predisposition to develop, Huntington's disease in a subject, the method comprising (a) evaluating the characteristics of huntingtin nucleic acid in a sample from the subject, wherein the evaluation comprises detecting the huntingtin (CAG) n region shown in SEQ ID NO:5 in the sample; and (b) comparing the characteristics found in (a) with a similar analysis from an individual with no family history of Huntington's disease, where the nucleic acid has from 11 to 34 (CAG) repeats, the presence of, or predisposition to develop, Huntington's disease being indicated if those characteristics in the huntingtin (CAG) n region differ. The characteristics of huntingtin nucleic acid may be evaluated by Southern blot, northern blot, or polymerase chain reaction analysis. In an eighth aspect, the invention provides the use of: (a) a nucleic acid molecule of the second aspect or a vector of the third aspect; (b) a polypeptide of the first aspect; and/or (c) a host cell of the fourth aspect in the preparation of a medicament. The medicament may be for treating, delaying or preventing a neurodegenerative disorder, preferably Huntington's disease, and may be for gene therapy. Preferably, the nucleic acid has from 11 to 34 (CAG) repeats and/or the polypeptide has from 11 to 34 Gln repeats, said repeats being consecutive. In a further aspect, the invention provides a diagnostic and/or immunoassay kit comprising at least one container and; (a) a nucleic acid molecule of the second aspect, optionally labelled; or (b) an antibody of the fifth aspect, optionally labelled. In a still further aspect, the invention provides a pharmaceutical composition comprising: (a) a nucleic acid molecule of the second aspect or a vector of the third aspect; (b) a polypeptide of the first aspect; and/or (c) a host cell of the fourth aspect in admixture with pharmaceutically acceptable carrier. In a yet further aspect, the invention provides process for the preparation of a polypeptide of the first aspect of the invention, the process comprising culturing a host cell according to of the fourth aspect under conditions whereby the polypeptide is expressed, and purifying or isolating the polypeptide. A functional huntingtin gene with a (CAG) n repeat of the normal range of 11-34 copies may be used in the manufacture of a medicament for gene therapy of a symptomatic or presymptomatic patient, the medicament being for administration to the desired cells of such patient in need of such treatment, in a manner that permits the expression of the huntingtin protein provided by such gene, for a time and in a quantity sufficient to provide the huntingtin function to the cells of such patient. Alternatively, a functional huntingtin antisense gene may be used in the manufacture of such a medicament which is for administration to the desired cells of such patient in need of such treatment, in a manner that permits the expression of huntingtin antisense RNA provided by such gene, for a time and in a quantity sufficient to inhibit huntingtin mRNA expression in the cells of such patient, or a functional huntingtin gene may be used in the manufacture of such a medicament which is for administration to the cells of such patient in need of such gene; the functional huntingtin gene may contain a (CAG) n repeat size between 11-34 copies. A method for diagnosing Huntington's disease or a predisposition to develop Huntington's disease in a patient, may comprise determining the number of (CAG) n repeats present in the huntingtin gene in such patient and especially in the affected tissue of such patient. Huntington's disease may be treated in a patient, decreasing the number of huntingtin (CAG) n repeats in the huntingtin gene in the desired cells of such patient. Brief Description of the Drawings FIGURE 1. Long-range restriction map of the HD candidate region. A partial long range restriction map of 4p16.3 is shown (adapted from Lin et al., Somat. Cell Mol. Genet. 17 :481-488 (1991)). The HD candidate region determined by recombination events is depicted as a hatched line between D4S10 and D4S98. The portion of the HD candidate region implicated as the site of the defect by linkage disequilibrium haplotype analysis (MacDonald et al., Nature Genet. 1 :99-103 (1992) is shown as a filled box. Below the map schematic, the region from D4S180 to D4S182 is expanded to show the cosmid contig (averaging 40 kb/cosmid). The genomic coverage and where known the transcriptional orientation (arrow 5' to 3') of the huntingtin (IT15), IT11, IT10C3 and ADDA genes is also shown. Locus names above the map denote selected polymorphic markers that have been used in HD families. The positions of D4S127 and D4S95 which form the core of haplotype in the region of maximum disequilibrium are also shown in the cosmid contig. Restriction sites are given for Not I (N), Mlu I (M) and Nru I (R). Sites displaying complete digestion are shown in boldface while sites subject to frequent incomplete digestion are shown as lighter symbols. Brackets around the "N" symbols indicate the presence of additional clustered Not I sites. FIGURE 2. Northern blot analysis of the huntingtin (IT15) transcript. Results of the hybridization of IT15A to a Northern blot of RNA from normal (lane 1) and HD homozygous (lane 2 and 3) lymphoblasts are shown. A single RNA of about 11 kb was detected in all three samples, with slight apparent variations being due to unequal RNA concentrations. The HD homozygotes are independent, deriving from the large an American family (lane 2) and the large Venezuelan family (lane 3), respectively. The Venezuelan HD chromosome has a 4p16.3 haplotype of "5 2 2" defined by a (GT) n polymorphism at D4S127 and VNTR and TaqI RFLPs at D4S95. The American homozygote carries the most common 4p16.3 haplotype found on HD chromosomes: "2 11 1" (MacDonald et al., Nature Genet. 1 :99-103 (1992)). FIGURE 3. Schematic of cDNA clones defining the IT15 transcript. Five cDNAs are represented under a schematic of the composite IT15 sequence. The thin line corresponds to untranslated regions. The thick line corresponds to coding sequence, assuming initiation of translation at the first Met codon in the open reading frame. Stars mark the positions of the following exon clones 5' to 3': DL83D3-8, DL83D3-1, DL228B6-3, DL228B6-5, DL228B6-13, DL69F7-3, DL178H4-6, DL118F5-U and DL134B9-U4. The composite sequence was derived as follows. From 22 bases 3' to the putative initiator Met ATG, the sequence was compiled from the cDNA clones and exons shown. There are 9 bases of sequence intervening between the 3' end of IT16B and the 5' end of IT15B. These were by PCR amplification of first strand cDNA and sequencing of the PCR product. At the 5' end of the composite sequence, the cDNA clone IT16C terminates 27 bases upstream of the (CAG) n . However, when IT16C was identified, we had already generated genomic sequence surrounding the (CAG) n in an attempt to generate new polymorphisms. This sequence matched the IT16C sequence, and extended it 337 bases upstream, including the apparent Met initiation codon. FIGURE 4. Composite sequence of huntingtin (IT15)(SEQ ID NO:5 and SEQ ID NO:6). The composite DNA sequence of huntingtin (IT15) is shown (SEQ ID NO:5). The predicted protein product (SEQ ID NO:6) is shown below the DNA sequence, based on the assumption that translation begins at the first in-frame methionine of the long open reading frame. FIGURE 5. DNA sequence analysis of the (CAG) n repeat. DNA sequence shown in panels 1, 2 and 3, demonstrates the variation in the (CAG) n repeat detected in normal cosmid L191F1 (1), cDNA IT16C (2), and HD cosmid GUS72-2130. Panels 1 and 3 were generated by direct sequencing of cosmid subclones using the following primer (SEQ ID NO:1): Panel 2 was generated using the pBSKII T7 primer (SEQ ID NO:2): FIGURE 6. PCR analysis of the (CAG) n repeat in a Venezuelan HD sibship with some offspring displaying juvenile onset. Results of PCR analysis of a sibship in the Venezuela HD pedigree are shown. Affected individuals are represented by shaded symbols. Progeny are shown as triangles for confidentiality. AN1, AN2 and AN3 mark the positions of the allelic products from normal chromosomes. AE marks the range of PCR products from the HD chromosome. The intensity of background constant bands, which represent a useful reference for comparison of the above PCR products, varies with slight differences in PCR conditions. The PCR products from cosmids L191F1 and GUS72-2130 are loaded in lanes 12 and 13 and have 18 and 48 CAG repeats, respectively. FIGURE 7. PCR analysis of the (CAG) n repeat in a Venezuelan HD sibship with offspring homozygous for the same HD haplotype. Results of PCR analysis of a sibship from the Venezuela HD pedigree in which both parents are affected by HD are shown. Progeny are shown as triangles for confidentiality and no HD diagnostic information is given to preserve the blind status of investigators in the Venezuelan Collaborative Group. AN1 and AN2 mark the positions of the allelic products from normal parental chromosomes. AE marks the range of PCR products from the HD chromosome. The PCR products from cosmids L191F1 and GUS72-2130 are loaded in lanes 29 and 30 and have 18 and 48 CAG repeats, respectively. FIGURE 8. PCR analysis of the (CAG) n repeat in members of an American family with an individual homozygous for the major HD haplotype. Results of PCR analysis of members of an American family segregating the major HD haplotype. AN marks the range of normal alleles; AE marks the range of HD alleles. Lanes 1, 3, 4, 5, 7 and 8 represent PCR products from related HD heterozygotes. Lane 2 contains the PCR products from a member of the family homozygous for the same HD chromosome. Lane 6 contains PCR products from a normal individual. Pedigree relationships and affected status are not presented to preserve confidentiality. The PCR products from cosmids L191F1 and GUS72-2130 (which was derived from the individual represented in lane 2) are loaded in lanes 9 and 10 and have 18 and 48 CAG repeats, respectively. FIGURES 9 and 10. PCR analysis of the (CAG) n repeat in two families with supposed new mutation causing HD. Results of PCR analysis of two families in which sporadic HD cases representing putative new mutants are shown. Individuals in each pedigree are numbered by generation (Roman numerals) and order in the pedigree. Triangles are used to protect confidentiality. Filled symbols indicate symptomatic individuals. The different chromosomes segregating in the pedigree have been distinguished by extensive typing with polymorphic markers in 4p16.3 and have been assigned arbitrary numbers shown above the gel lanes. The starred chromosomes (3 in Figure 9, 1 in Figure 10) represent the presumed HD chromosome. AN denotes the range of normal alleles; AE denotes the range of alleles present in affected individuals and in their unaffected relatives bearing the same chromosomes. FIGURE 11. Comparison of (CAG) n Repeat Unit Number on Control and HD Chromosomes. Frequency distributions are shown for the number of (CAG) n repeat units observed on 425 HD chromosomes from 150 independent families, and from 545 control chromosomes. FIGURE 12. Comparison of (CAG)n Repeat Unit Number on Maternally and Paternally Transmitted HD Chromosomes. Frequency distributions are shown for the 134 and 161 HD chromosomes from Figure 11 known to have been transmitted from the mother (Panel A) and father (Panel B), respectively. The two distributions differ significantly based on a t-test (t 272.3 =5.34, p < 0.0001). FIGURE 13. Comparison of (CAG) n Repeat Unit Number on HD Chromosomes from Three Large Families with Different HD Founders. Frequency distributions are shown for 75, 25 and 35 HD chromosomes from the Venezuelan HD family (Panel A) (Gusella, J.F., et al., Nature 306 :234-238 (1983); Wexler, N.S., et al., Nature 326 :194-197 (1987)), Family Z (Panel B) and Family D (Panel C) (Folstein, S.E., et al., Science 229 :776-779 (1985)), respectively. The Venezuelan distribution did not differ from the overall HD chromosome distribution in Figure 11 (t 79.7 =1.58, p <0.12). Both Family Z and Family D did produce distributions significantly different from the overall HD distribution (t 42.2 =6.73, p<0.0001 and t 458 =2.90, p<0.004, respectively). Figure 14. Relationship of (CAG) n Repeat Length in Parents and Corresponding Progeny. Repeat length on the HD chromosome in mothers (Panel A) or fathers (Panel B) is plotted against the repeat length in the corresponding offspring. A total of 25 maternal transmissions and 37 paternal transmissions were available for typing. FIGURE 15. Amplification of the HD (CAG) n Repeat From Sperm and Lymphoblast DNA. DNA from sperm (S) and lymphoblasts (L) for 5 members (pairs 1-5) of the Venezuelan HD pedigree aged 24-30 were used for PCR amplification of the HD (CAG) n repeat. The lower band in each lane derives from the normal chromosome. FIGURE 16. Relationship of Repeat Unit Length with Age of Onset. Age of onset was established for 234 diagnosed HD gene carriers and plotted against the repeat length observed on both the HD and normal chromosomes in the corresponding lymphoblast lines. Detailed Description of the Invention In the following description, reference will be made to various methodologies known to those of skill in the art of molecular genetics and biology. The IT15 gene described herein is a gene from the proximal portion of the 500 kb segment between human chromosome 4 markers D4S180 and D4S182 . The huntingtin gene spans about 210 kb of DNA and encodes a previously undescribed protein of about 348 kDa. The huntingtin reading frame contains a polymorphic (CAG) n trinucleotide repeat with at least 17 alleles in the normal human population, where the repeat number varies from 11 to about 34 CAG copies in such alleles. This is the gene of the human chromosome that, as shown herein, suffers the presence of an unstable, expanded number of CAG trinucleotide repeats in Huntington's disease patients, such that the number of CAG repeats in the huntingtin gene increases to a range of 37 to at least 86 copies. These results are the basis of a conclusion that the huntingtin gene encodes a protein called "huntingtin," and that in such huntingtin gene the increase in the number of CAG repeats to a range of greater than about 37 repeats is the alteration that underlies the dominant phenotype of Huntington's disease. As used herein huntingtin gene is also called the Huntington's disease gene. It is to be understood that the description below is applicable to any gene in which a CAG repeat within the gene is amplified in an aberrant manner resulting in a change in the regulation, localization, stability or translatability of the mRNA containing such amplified CAG repeat that is transcribed from such gene. I. Cloning Of Huntingtin DNA And Expression Of Huntingtin Protein The identification of huntingtin DNA and protein as the altered gene in Huntington's disease patients is exemplified below. In addition to utilizing the exemplified methods and results for the identification of deletions of the huntingtin gene in Huntington's disease patients, and for the isolation of the native human huntingtin gene, the sequence information presented in Figure 4 represents a nucleic acid and protein sequence, that, when inserted into a linear or circular recombinant nucleic acid construct such as a vector, and used to transform a host cell, will provide copies of huntingtin DNA and huntingtin protein that are useful sources for the native huntingtin DNA and huntingtin protein for the methods of the invention. Such methods are known in the art and are briefly outlined below. The process for genetically engineering the huntingtin coding sequence, for expression under a desired promoter, is facilitated through the cloning of genetic sequences which are capable of encoding such huntingtin protein. Such cloning technologies can utilize techniques known in the art for construction of a DNA sequence encoding the huntingtin protein, such as, for example, polymerase chain reaction technologies utilizing the huntingtin sequence disclosed herein to isolate the huntingtin gene anew, or an allele thereof that varies in the number of CAG repeats in such gene, or polynucleotide synthesis methods for constructing the nucleotide sequence using chemical methods. Expression of the cloned huntingtin DNA provides huntingtin protein. As used herein, the term "genetic sequences" is intended to refer to a nucleic acid molecule of DNA or RNA, preferably DNA. Genetic sequences that are capable of being operably linked to DNA encoding huntingtin protein, so as to provide for its expression and maintenance in a host cell are obtained from a variety of sources, including commercial sources, genomic DNA, cDNA, synthetic DNA, and combinations thereof. Since the genetic code is universal, it is to be expected that any DNA encoding the huntingtin amino acid sequence of the invention will be useful to express huntingtin protein in any host, including prokaryotic (bacterial) hosts, eukaryotic hosts (plants, mammals (especially human), insects, yeast, and especially any cultured cell populations). If it is desired to select anew a gene encoding huntingtin from a library that is thought to contain a huntingtin gene, such library can be screened and the desired gene sequence identified by any means which specifically selects for a sequence coding for the huntingtin gene or expressed huntingtin protein such as, for example, a) by hybridization (under stringent conditions for DNA:DNA hybridization) with an appropriate huntingtin DNA probe(s) containing a sequence specific for the DNA of this protein, such sequence being that provided in Figure 4 or a functional derivative thereof that is, a shortened form that is of sufficient length to identify a clone containing the huntingtin gene, or b) by hybridization-selected translational analysis in which native huntingtin mRNA which hybridizes to the clone in question is translated in vitro and the translation products are further characterized for the presence of a biological activity of huntingtin, or c) by immunoprecipitation of a translated huntingtin protein product from the host expressing the huntingtin protein. When a human allele does not encode the identical sequence to that of Figure 4, it can be isolated and identified as being huntingtin DNA using the same techniques used herein, and especially PCR techniques to amplify the appropriate gene with primers based on the sequences disclosed herein. Many polymorphic probes useful in the fine localization of genes on chromosome 4 are known and available (see, for example, "ATCC/NIH Repository Catalogue of Human and Mouse DNA Probes and Libraries," fifth edition, 1991, pages 4-6. For example, a useful D4S10 probe is clone designation pTV20 (ATCC 57605 and 57604); H5.52 (ATCC 61107 and 61106) and F5.53 (ATCC 61108). Human chromosome 4-specific libraries are known in the art and available from the ATCC for the isolation of probes ("ATCC/NIH Repository Catalogue of Human and Mouse DNA Probes and Libraries," fifth edition, 1991, pages 72-73), for example, LL04NS01 and LL04NS02 (ATCC 57719 and ATCC57718) are useful for these purposes. It is not necessary to utilize the exact vector constructs exemplified in the invention; equivalent vectors can be constructed using techniques known in the art. For example, the sequence of the huntingtin DNA is provided herein, (see Figure 4) and this sequence provides the specificity for the huntingtin gene; it is only necessary that a desired probe contain this sequence, or a portion thereof sufficient to provide a positive indication of the presence of the huntingtin gene. Huntingtin genomic DNA may or may not include naturally occurring introns. Moreover, such genomic DNA can be obtained in association with the native huntingtin 5' promoter region of the gene sequences and/or with the native huntingtin 3' transcriptional termination region. Such huntingtin genomic DNA can also be obtained in association with the genetic sequences which encode the 5' non-translated region of the huntingtin mRNA and/or with the genetic sequences which encode the huntingtin 3' non-translated region. To the extent that a host cell can recognize the transcriptional and/or translational regulatory signals associated with the expression of huntingtin mRNA and protein, then the 5' and/or 3' non-transcribed regions of the native huntingtin gene, and/or, the 5' and/or 3' non-translated regions of the huntingtin mRNA can be retained and employed for transcriptional and translational regulation. Genomic DNA can be extracted and purified from any host cell, especially a human host cell possessing chromosome 4, by means well known in the art. Genomic DNA can be shortened by means known in the art, such as physical shearing or restriction digestion, to isolate the desired huntingtin gene from a chromosomal region that otherwise would contain more information than necessary for the utilization of the huntingtin gene in the hosts of the invention. For example, restriction digestion can be utilized to cleave the full-length sequence at a desired location. Alternatively, or in addition, nucleases that cleave from the 3'-end of a DNA molecule can be used to digest a certain sequence to a shortened form, the desired length then being identified and purified by polymerase chain reaction technologies, gel electrophoresis, and DNA sequencing. Such nucleases include, for example, Exonuclease III and Bal 31. Other nucleases are well known in the art. Alternatively, if it is known that a certain host cell population expresses huntingtin protein, then cDNA techniques known in the art can be utilized to synthesize a cDNA copy of the huntingtin mRNA present in such population. For cloning the genomic or cDNA nucleic acid that encodes the amino acid sequence of the huntingtin protein into a vector, the DNA preparation can be ligated into an appropriate vector. The DNA sequence encoding huntingtin protein can be inserted into a DNA vector in accordance with conventional techniques, including blunt-ending or staggered-ending termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulations are well known in the art. When the huntingtin DNA coding sequence and an operably linked promoter are introduced into a recipient eukaryotic cell (preferably a human host cell) as a non-replicating, non-integrating, molecule, the expression of the encoded huntingtin protein can occur through the transient (nonstable) expression of the introduced sequence. Preferably the coding sequence is introduced on a DNA molecule, such as a closed circular or linear molecule that is capable of autonomous replication. If integration into the host chromosome is desired, it is preferable to use a linear molecule. If stable maintenance of the huntingtin gene is desired on an extrachromosomal element, then it is preferable to use a circular plasmid form, with the appropriate plasmid element for autonomous replication in the desired host. The desired gene construct, providing a gene coding for the huntingtin protein, and the necessary regulatory elements operably linked thereto, can be introduced into a desired host cells by transformation, transfection, or any method capable of providing the construct to the host cell. A marker gene for the detection of a host cell that has accepted the huntingtin DNA can be on the same vector as the huntingtin DNA or on a separate construct for co-transformation with the huntingtin coding sequence construct into the host cell. The nature of the vector will depend on the host organism. Suitable selection markers will depend upon the host cell. For example, the marker can provide biocide resistance, e.g., resistance to antibiotics, or heavy metals, such as copper, or the like. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector can be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species. When it is desired to use S. cerevisiae as a host for a shuttle vector, preferred S. cerevisiae yeast plasmids include those containing the 2-micron circle, etc., or their derivatives. Such plasmids are well known in the art and are commercially available. Oligonucleotide probes specific for the huntingtin sequence can be used to identify clones to huntingtin and can be designed de novo from the knowledge of the amino acid sequence of the protein as provided herein in Figure 4 or from the knowledge of the nucleic acid sequence of the DNA encoding such protein as provided herein in Figure 4 or of a related protein. Alternatively, antibodies can be raised against the huntingtin protein and used to identify the presence of unique protein determinants in transformants that express the desired cloned protein. A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a huntingtin protein if that nucleic acid contains expression control sequences which contain transcriptional regulatory information and such sequences are "operably linked" to the huntingtin nucleotide sequence which encode the huntingtin polypeptide. An operable linkage is a linkage in which a sequence is connected to a regulatory sequence (or sequences) in such a way as to place expression of the sequence under the influence or control of the regulatory sequence. If the two DNA sequences are a coding sequence and a promoter region sequence linked to the 5' end of the coding sequence, they are operably linked if induction of promoter function results in the transcription of mRNA encoding the desired protein and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the expression regulatory sequences to direct the expression of the protein, antisense RNA, or (3) interfere with the ability of the DNA template to be transcribed. Thus, a promoter region would be operably linked to a DNA sequence if the promoter was capable of effecting transcription of that DNA sequence. The precise nature of the regulatory regions needed for gene expression can vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating (non-coding) sequences involved with initiation of transcription and translation respectively, such as the TATA box, capping sequence, CAAT sequence, and the like, with those elements necessary for the promoter sequence being provided by the promoters of the invention. Such transcriptional control sequences can also include enhancer sequences or upstream activator sequences, as desired. The vectors of the invention can further comprise other operably linked regulatory elements such as DNA elements which confer antibiotic resistance, or origins of replication for maintenance of the vector in one or more host cells. In another embodiment, especially for maintenance of the vectors of the invention in prokaryotic cells, or in yeast S. cerevisiae cells, the introduced sequence is incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors can be employed for this purpose. In Bacillus hosts, integration of the desired DNA can be necessary. Expression of a protein in eukaryotic hosts such as a human cell requires the use of regulatory regions functional in such hosts. A wide variety of transcriptional and translational regulatory sequences can be employed, depending upon the nature of the host. Preferably, these regulatory signals are associated in their native state with a particular gene which is capable of a high level of expression in the specific host cell, such as a specific human tissue type. In eukaryotes, where transcription is not linked to translation, such control regions may or may not provide an initiator methionine (AUG) codon, depending on whether the cloned sequence contains such a methionine. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis in the host cell. If desired, the non-transcribed and/or non-translated regions 3' to the sequence coding for the huntingtin protein can be obtained by the above-described cloning methods. The 3'-non-transcribed region of the native human huntingtin gene can be retained for its transcriptional termination regulatory sequence elements, or for those elements which direct polyadenylation in eukaryotic cells. Where the native expression control sequences signals do not function satisfactorily in a host cell, then sequences functional in the host cell can be substituted. It may be desired to construct a fusion product that contains a partial coding sequence (usually at the amino terminal end) of a first protein or small peptide and a second coding sequence (partial or complete) of the huntingtin protein at the carboxyl end. The coding sequence of the first protein can, for example, function as a signal sequence for secretion of the huntingtin protein from the host cell. Such first protein can also provide for tissue targeting or localization of the huntingtin protein if it is to be made in one cell type in a multicellular organism and delivered to another cell type in the same organism. Such fusion protein sequences can be designed with or without specific protease sites such that a desired peptide sequence is amenable to subsequent removal. The expressed huntingtin protein can be isolated and purified from the medium of the host in accordance with conventional conditions, such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, or the like. For example, affinity purification with anti-huntingtin antibody can be used. A protein having the amino acid sequence shown in Figure 3 can be made, or a shortened peptide of this sequence can be made, and used to raised antibodies using methods well known in the art. These antibodies can be used to affinity purify or quantitate huntingtin protein from any desired source. If it is necessary to extract huntingtin protein from the intracellular regions of the host cells, the host cells can be collected by centrifugation, or with suitable buffers, lysed, and the protein isolated by column chromatography, for example, on DEAE-cellulose, phosphocellulose, polyribocytidylic acid-agarose, hydroxyapatite or by electrophoresis or immunoprecipitation. II. Use Of Huntingtin For Diagnostic And Treatment Purposes It is to be understood that although the following discussion is specifically directed to human patients, the teachings are also applicable to any animal that expresses huntingtin and in which alteration of huntingtin, especially the amplification of CAG repeat copy number, leads to a defect in huntingtin gene (structure or function) or huntingtin protein (structure or function or expression), such that clinical manifectations such as those seen in Huntington's disease patients are found. It is also to be understood that the methods referred to herein are applicable to any patient suspected of developing/having Huntington's disease, whether such condition is manifest at a young age or at a more advanced age in the patient's life. It is also to be understood that the term "patient" does not imply that symptoms are present, and patient includes any individual it is desired to examine or treat using the methods of the invention. The diagnostic and screening methods of the invention are especially useful for a patient suspected of being at risk for developing Huntington's disease based on family history, or a patient in which it is desired to diagnose or eliminate the presence of the Huntington's disease condition as a causative agent behind a patient's symptoms. It is to be understood that to the extent that a patient's symptoms arise due to the alteration of the CAG repeat copy numbers in the huntingtin gene, even without a diagnosis of Huntington's disease, the methods of the invention can identify the same as the underlying basis for such condition. According to the invention, presymptomatic screening of an individual in need of such screening for their likelihood of developing Huntington's disease is now possible using DNA encoding the huntingtin gene of the invention, and specifically, DNA having the sequence of the normal human huntingtin gene. The screening method of the invention allows a presymptomatic diagnosis, including prenatal diagnosis, of the presence of an aberrant huntingtin gene in such individuals, and thus an opinion concerning the likelihood that such individual would develop or has developed Huntington's disease or symptoms thereof. This is especially valuable for the identification of carriers of altered huntingtin gene alleles where such alleles possess an increased number of CAG repeats in their huntingtin gene, for example, from individuals with a family history of Huntington's disease. Especially useful for the determination of the number of CAG repeats in the patient's huntingtin gene is the use of PCR to amplify such region or DNA blotting techniques. For example, in the method of screening, a tissue sample would be taken from such individual, and screened for (1) the presence of the 'normal' human huntingtin gene, especially for the presence of a "normal" range of 11-34 CAG copies in such gene. The human huntingtin gene can be characterized based upon, for example, detection of restriction digestion patterns in 'normal' versus the patient's DNA, including RFLP analysis, using DNA probes prepared against the huntingtin sequence (or a functional fragment thereof) taught in the invention. Similarly, huntingtin mRNA can be characterized and compared to normal huntingtin mRNA (a) levels and/or (b) size as found in a human population not at risk of developing Huntington's disease using similar probes. Lastly, huntingtin protein can be (a) detected and/or (b) quantitated using a biological assay for huntingtin, for example, using an immunological assay and anti-huntingtin antibodies. When assaying huntingtin protein, the immunological assay is preferred for its speed. Methods of making antibody against the huntingtin are well known in the art. An (1) aberrant huntingtin DNA size pattern, such as an aberrant huntingtin RFLP, and/or (2) aberrant huntingtin mRNA sizes or levels and/or (3) aberrant huntingtin protein levels would indicate that the patient has developed or is at risk for developing a huhtingtin-associated symptom such as a symptom associated with Huntington's disease. The screening and diagnostic methods of the invention do not require that the entire huntingtin DNA coding sequence be used for the probe. Rather, it is only necessary to use a fragment or length of nucleic acid that is sufficient to detect the presence of the huntingtin gene in a DNA preparation from a normal or affected individual, the absence of such gene, or an altered physical property of such gene (such as a change in electrophoretic migration pattern). Prenatal diagnosis can be performed when desired, using any known method to obtain fetal cells, including amniocentesis, chorionic villous sampling (CVS), and fetoscopy. Prenatal chromosome analysis can be used to determine if the portion of chromosome 4 possessing the normal huntingtin gene is present in a heterozygous state, and PCR amplification or DNA blotting utilized for estimating the size of the CAG repeat in the huntingtin gene. The huntingtin DNA can be synthesized, especially, the CAG repeat region can be amplified and, if desired, labeled with a radioactive or nonradioactive reporter group, using techniques known in the art (for example, see Eckstein, F., Ed., Oligonucleotides and Analogues: A Practical Approach, IRS Press at Oxford University Press, New York, 1992); and Kricka, L.J., Ed., Nonisotopic DNA Probe Techniques, Academic Press, San Diego, (1992)). Functional huntingtin DNA may be used in the manufacture of a medicament for treating Huntington's disease in a patient in need of such treatment, the medicament being for administration to the cells of such patient, preferably prior to such symptomatic state that indicates the death of many of the patient's neuronal cells which it is desired to target with the method of the invention. The replacement huntingtin DNA is provided in a manner and amount that permits the expression of the huntingtin protein provided by such gene, for a time and in a quantity sufficient to treat such patient. Many vector systems are known in the art to provide such delivery to human patients in need of a gene or protein missing from the cell. For example, adenovirus or retrovirus systems can be used, especially modified retrovirus systems and especially herpes simplex virus systems. Such methods are provided for, in, for example, the teachings of Breakefield, X.A. et al., The New Biologist 3 :203-218 (1991); Huang, Q. et al., Experimental Neurology 115 :303-316 (1992), WO93/03743 and WO90/09441 . Methods of antisense strategies are known in the art (see, for example, Antisense Strategies, Baserga, R. et al. , Eds., Annals of the New York Academy of Sciences, volume 660, 1992). A gene encoding an expressible sequence that transcribes huntingtin antisense RNA may be used in the manufacture of a medicament for treating Huntington's disease in a patient in need of such treatment, the medicament being for administration to the cells of such patient, preferably prior to such symptomatic state that indicates the death of many of the patient's neuronal cells which it is desired to target with the method of the invention. The replacement huntingtin antisense RNA gene is provided in a manner and amount that permits the expression of the antisense RNA provided by such gene, for a time and in a quantity sufficient to treat such patient, and especially in an amount to inhibit translation of the aberrant huntingtin mRNA that is being expressed in the cells of such patient. As above, many vector systems are known in the art to provide such delivery to human patients in need of a gene or protein which is altered in the patients' cells. For example, adenovirus or retrovirus systems can be used, especially modified retrovirus systems and especially herpes simplex virus systems. Such methods are provided for, in, for example, the teachings of Breakefield, X.A. et al., The New Biologist 3 :203-218 (1991); Huang, Q. et al., Experimental Neurology 115 :303-316 (1992), WO93/03743 and WO90/09441. Delivery of a DNA sequence encoding a functional huntingtin protein, such as the amino acid encoding sequence of Figure 4, will effectively replace the:altered huntingtin gene of the invention, and inhibit, and/or stop and/or regress the symptoms that are the result of the interference to huntingtin gene expression due to an increased number of CAG repeats, such as 37 to 86 repeats in the huntingtin gene as compared to the 11-34 CAG repeats found in human populations not at risk for developing Huntington's disease. Because Huntington's disease is characterized by a loss of neurons that is most severe in the caudate and putamen regions of the brain, the method of treatment of the invention is most effective when the replacement huntingtin gene is provided to the patient early in the course of the disease, prior to the loss of many neurons due to cell death. For that reason, presymptomatic screening methods according to the invention are important in identifying those individuals in need of treatment by the method of the invention, and such treatment preferably is provided while such individual is presymptomatic. An antagonist to the aberrant huntingtin protein may be used in the manufacture of a medicament for treating Huntington's disease in a patient in need of such treatment, the medicament being for administration in the cells of such patient. Although the use is specifically described for DNA-DNA probes, it is to be understood that RNA possessing the same sequence information as the DNA of the invention can be used when desired. For diagnostic assays, huntingtin antibodies are useful for quantitating and evaluating levels of huntingtin protein, and are especially useful in immunoassays and diagnostic kits. In another embodiment, the present invention relates to an antibody having binding affinity to an huntingtin polypeptide, or a binding fragment thereof. In a preferred embodiment, the polypeptide has the amino acid sequence set forth in SEQ ID NO:6, or mutant or species variation thereof, or at least 7 contiguous amino acids thereof (preferably, at least 10, 15, 20, or 30 contiguous amino acids thereof). Those which bind selectively to huntingtin would be chosen for use in methods which could include, but should not be limited to, the analysis of altered huntingtin expression in tissue containing huntingtin. The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies. Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment; the Fab' fragments, and the Fab fragments. Of special interest to the present invention are antibodies to huntingtin (or their functional derivatives) which are produced in humans, or are "humanized" (i.e. non-immunogenic in a human) by recombinant or other technology. Humanized antibodies may be produced, for example by replacing an immunogenic portion of an antibody with a corresponding, but non-immunogenic portion (i.e. chimeric antibodies) (Robinson, R.R. et al., International Patent Publication PCT/US86/02269; Akira, K. et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison, S.L. et al ., European Patent Application 173,494; Neuberger, M.S. et al., PCT Application WO 86/01533; Cabilly, S. et al., European Patent Application 125,023; Better, M. et al., Science 240 :1041-1043 (1988); Liu, A.Y. et al., Proc. Natl. Acad. Sci. USA 84 :3439-3443 (1987); Liu, A.Y. et al., J. Immunol. 139 :3521-3526 (1987); Sun, L.K. et al., Proc. Natl. Acad. Sci. USA 84 :214-218 (1987); Nishimura, Y. et al., Canc. Res. 47 :999-1005 (1987); Wood, C.R. et al., Nature 314 :446-449 (1985)); Shaw et al., J. Natl. Cancer Inst. 80 :1553-1559 (1988). General reviews of "humanized" chimeric antibodies are provided by Morrison, S.L. ( Science, 229 :1202-1207 (1985)) and by Oi, V.T. et al., BioTechniques 4:214 (1986)). Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (Jones, P.T. et al., Nature 321 :552-525 (1986); Verhoeyan et al., Science 239 :1534 (1988); Beidler, C.B. et al., J. Immunol. 141 :4053-4060 (1988)). In another embodiment, the present invention relates to a hybridoma which produces the above-described monoclonal antibody, or binding fragment thereof. A hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody. In general, techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell, "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology ," Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth et al., J. Immunol. Methods 35 :1-21 (1980)). Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art. Such methods include subcutaneous or interperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection. The polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity. Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or β-galactosidase) or through the inclusion of an adjuvant during immunization. For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al., Exp. Cell Res. 175 :109-124 (1988)). Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, supra (1984)). For polyclonal antibodies, antibody containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures. In another embodiment of the present invention, the above-described antibodies are detectably labeled. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horse radish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see (Sternberger et al. , J. Histochem. Cytochem. 18 :315 (1970); Bayer et al., Meth. Enzym. 62 :308 (1979); Engval et al., Immunol. 109 :129 (1972); Goding, J. Immunol. Meth. 13 :215 (1976)). The labeled antibodies of the present invention can be used for in vitro, in vivo , and in situ assays to identify cells or tissues which express a specific peptide. The above-described antibodies may be immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., "Handbook of Experimental Immunology " 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby et al., Meth. Enzym. 34 Academic Press, N.Y. (1974)). The immobilized antibodies of the present invention can be used for in vitro, in vivo , and in situ assays as well as in immunochromotography. Furthermore, one skilled in the art can readily adapt currently available procedures, as well as the techniques, methods and kits disclosed above with regard to antibodies, to generate peptides capable of binding to a specific peptide sequence in order to generate rationally designed antipeptide peptides, for example see Hurby et al., "Application of Synthetic Peptides: Antisense Peptides", In Synthetic Peptides, A User's Guide, W.H. Freeman, NY, pp. 289-307 (1992), and Kaspczak et al., Biochemistry 28 :9230-8 (1989). Anti-peptide peptides can be generated in one of two fashions. First, the anti-peptide peptides can be generated by replacing the basic amino acid residues found in the huntingtin peptide sequence with acidic residues, while maintaining hydrophobic and uncharged polar groups. For example, lysine, arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine. The manner and method of carrying out the present invention can be more fully understood by those of skill by reference to the following examples. Examples The gene causing Huntington's disease has been mapped in 4p16.3 but has previously eluded identification. The invention uses haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, huntingtin ( IT15 ), isolated using cloned "trapped" exons from a cosmid contig of the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG) n repeat longer than the normal range of about 11 to about 34 copies was observed on HD chromosomes from all 75 disease families examined, comprising a wide range of ethnic backgrounds and 4p16.3 haplotypes. The (CAG) n repeat, which varies from 37 to at least 86 copies on HD chromosomes appears to be located within the coding sequence of a predicted about 348 kDa protein that is widely expressed but unrelated to any known gene. Thus, the Huntington's disease mutation involves an unstable DNA segment, similar to those described in fragile X syndrome and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype. The following protocols and experimental details are referenced in the examples that follow. HD Cell Lines. Lymphoblast cell lines from HD families of varied ethnic backgrounds used for genetic linkage and disequilibrium studies (Conneally et al., Genomics 5 :304-308 (1989); MacDonald et al., Nature Genet. 1 :99-103 (1992)) have been established (Anderson and Gusella, In Vitro 20 :856-858 (1984)) in the Molecular Neurogenetics Unit, Massachusetts General Hospital, over the past 13 years. The Venezuelan HD pedigree is an extended kindred of over 10,000 members in which all affected individuals have inherited the HD gene from a common founder (Gusella et al., Nature 306 :234-238 (1983); Gusella et al., Science 225 :1320-1326 (1984); Wexler et al., Nature 326 :194-197 (1987)). DNA / RNA Blotting. DNA was prepared from cultured cells and DNA blots prepared and hybridized as described (Gusella et al., Proc. Natl. Acad. Sci. USA 76 :5239-5243 (1979); Gusella et al., Nature 306 :234-238 (1983)). RNA was prepared and Northern blotting performed as described in Taylor et al., Nature Genet. 3 :223-227 (1992). Construction of Cosmid Contig. The initial construction of the cosmid contig was by chromosome walking from cosmids L19 and BJ56 (Allitto et al ., Genomics 9 :104-112 (1991); Lin et al., Somat. Cell Mol. Genet. 17 :481-488 (1991)). Two libraries were employed, a collection of Alu-positive cosmids from the reduced cell hybrid H39-8C10 (Whaley et al., Som. Cell Mol. Genet. 17 :83-91 (1991)) and an arrayed flow-sorted chromosome 4 cosmid library (NM87545) provided by the Los Alamos National Laboratory. Walking was accomplished by hybridization of whole cosmid DNA, using suppression of repetitive and vector sequences, to robot-generated high density filter grids (Nizetic, D. et al., Proc. Natl. Acad. Sci. USA 88 :3233-3237 (1991); Lehrach, H. et al., in Genome Analysis: Genetic and Physical Mapping, Volume 1 , Davies, K.E. et al. , Ed., Cold Spring Harbor Laboratory Press, 1991, pp. 39-81). Cosmids L1C2, L69F7, L228B6 and L83D3 were first identified by hybridization of YAC clone YGA2 to the same arrayed library (Bates et al ., Nature Genet. 1 :180-187 (1992); Baxendale et al. , Nucleic Acids Res. 19 :6651 (1991)). HD cosmid GUS72-2130 was isolated by standard screening of a GUS72 cosmid library using a single-copy probe. Cosmid overlaps were confirmed by a combination of clone-to-clone and clone-to-genomic hybridizations, single-copy probe hybridizations and restriction mapping. cDNA Isolation and Characterization. Exon probes were isolated and cloned as described (Buckler et al., Proc. Natl. Acad. Sci. USA 88 :4005-4009 (1991)). Exon probes and cDNAs were used to screen human 1ambdaZAPII cDNA libraries constructed from adult frontal cortex, fetal brain, adenovirus transformed retinal cell line RCA, and liver RNA. cDNA clones, PCR products and trapped exons were sequenced as described (Sanger et al., Proc. Natl. Acad. Sci. USA 74 :5463-5467 (1977)). Direct cosmid sequencing was performed as described (McClatchey et al., Hum. Mol. Genet. 1 :521-527 (1992)). Database searches were performed using the BLAST network service of National Center for Biotechnology Information (Altschul et al., J. Mol. Biol. 215 :403-410 (1990)). PCR Assay of the (CAG) n Repeat. Genomic primers (SEQ ID NO:3 and SEQ ID NO:4) flanking the (CAG) n repeat are: and PCR amplification was performed in a reaction volume of 25 µl using 50 ng of genomic DNA, 5 µg of each primer, 10 mM Tris, pH 8.3, 5mM KCl, 2mM MgCl 2 , 200 µM dNTPs, 10% DMSO, 0.1 unit Perfectmatch (Stratagene), 2.5 µCi 32 P-dCTP (Amersham) and 1.25 units Taq polymerase (Boehringer Mannheim). After heating to 94°C for 1.5 minutes, the reaction mix was cycled according to the following program: 40 X [1'@94°C;1'@60°C;2'@72°C]. 5 µl of each PCR reaction was diluted with an equal volume of 95 % formamide loading dye and heat denatured for 2 min. at 95°C. The products were resolved on 5% denaturing polyacrylamide gels. The PCR product from this reaction using cosmid L191F1 (CAG 18 ) as template was 247 bp. Allele sizes were estimated relative to a DNA sequencing ladder, the PCR products from sequenced cosmids, and the invariant background bands often present on the gel. Estimates of allelic variation were obtained by typing unrelated individuals of largely Western European ancestry, and normal parents of affected HD individuals from various pedigrees. Typing of HD and normal chromosomes in Examples 5-8. HD chromosomes were derived from symptomatic individuals and "at risk" individuals known to be gene carriers by linkage marker analysis. All HD chromosomes were from members of well-characterized HD families of varied ethnic backgrounds used previously for genetic linkage and disequilibrium studies (MacDonald, M.E., et al., Nature Genet. 1 :99-103 (1992); Conneally, P.M., et al., Genomics 5 :304-308 (1989)). Three of the 150 families used were large pedigrees, each descended from a single founder. The large Venezuelan HD pedigree is an extended kindred of over 13,000 members from which we typed 75 HD chromosomes (Gusella, J.F., et al., Nature 306 :234-238 (1983); Wexler, N.S., et al., Nature 326 :194-197 (1987)). Two other large families that have been described previously as Family Z and Family D, provided 25 and 35 HD chromosomes, respectively (Folstein, S.E., et al., Science 229 :776-779 (1985)). Normal chromosomes were taken from married-ins in the HD families and from unrelated normal individuals from non-HD families. The DNA tested for all individuals except four was prepared from lymphoblastoid cell lines or fresh blood (Gusella, J.F., et al., Nature 306 :234-238 (1983); Anderson and Gusella, In Vitro 20 :856-858 (1984)). In the exceptional cases, DNA was prepared from frozen cerebellum. No difference in the characteristics of the PCR products were observed between lymphoblastoid, fresh blood, or brain DNAs. For five members of the Venezuelan pedigree aged 24-30, we also prepared DNA by extracting pelleted sperm from semen samples. The length of the HD gene (CAG) n repeat for all DNAs was assessed using polymerase chain reaction amplification. Statistical analysis as set forth in Examples 5-8. Associations between repeat lengths and onset age were assessed by Pearson correlation coefficient and by multivariate regression to assess higher order associations. Comparisons of the distributions of repeat length for all HD chromosomes and those for individual families were made by analysis of variance and t-test contrasts between groups. The 95 % confidence bands were computed around the regression line utilizing the general linear models procedure of SAS (SAS Institute Inc., SAS/STAT User's Guide, Version 6, Fourth Edition, Volume 2 (SAS Institute Inc., Cary, N.C., pp. 846, 1989)). Example 1 Application of Exon Amplification to Obtain Trapped Cloned Exons The HD candidate region defined by discrete recombination events in well-characterized families spans 2.2 Mb between D4S10 and D4S98 as shown in Figure 1. The 500 kb segment between D4S180 and D4S182 displays the strongest linkage disequilibrium with HD , with about 1/3 of disease chromosomes sharing a common haplotype, anchored by multi-allele polymorphisms at D4S127 and D4S95 (MacDonald et al., Nature Genet. 1 :99-103 (1992)). Sixty-four overlapping cosmids spanning about 480 kb from D4S180 to a location between D4S95 and D4S182 have been isolated by a combination of information from YAC (Baxendale et al., Nucleic Acids Res. 19 :6651 (1991)) and cosmid probe hybridization to high density filter grids of a chromosome 4 specific library, as well as additional libraries covering this region. Sixteen of these cosmids providing the complete contig are shown in Figure 1. We have previously used exon amplification to identify ADDA, the α-adducin locus, IT10C3, a novel putative transporter gene, and IT11, a novel G protein-coupled receptor kinase gene in the region distal to D4S127 (Figure 1). We have now applied the exon amplification technique to cosmids from the region of the contig proximal to D4S127. This procedure produces "trapped" exon clones, which can represent single exons, or multiple exons spliced together and is an efficient method of obtaining probes for screening cDNA libraries. Individual cosmids were processed, yielding 9 exon clones in the region from cosmids L134B9 to L181B10. Two non-overlapping cDNAs were initially isolated using exon probes. IT15A was obtained by screening a transformed adult retinal cell cDNA library with exon clone DL118F5-U. IT16A was isolated by screening an adult frontal cortex cDNA library with a pool of three exon clones, DL83D3-8, DL83D3-1, and DL228B6-3. By Northern blot analysis, we discovered that IT15A and IT16A are in fact different portions of the same large approximately 10-11 kb transcript. Figure 2 shows an example of a Northern blot containing RNA from lymphoblastoid cell lines representing a normal individual and 2 independent homozygotes for HD chromosomes of different haplotypes. The same approximately 10-11 kb transcript was also detected in RNA from a variety of human tissues (liver, spleen, kidney, muscle and various regions of adult brain). IT15A and IT16A were used to "walk" in a number of human tissue cDNA libraries in order to obtain the full-length transcript. Figure 3 shows a representation of 5 cDNA clones which define the IT15 transcript, under a schematic of the composite sequence derived as described in the legend. Figure 3 also displays the locations on the composite sequence of the 9 trapped exon clones. The composite sequence of IT15, containing the entire predicted coding sequence, spans 10,366 bases including a tail of 18 A's as shown in Figure 4. An open reading frame of 9,432 bases begins with a potential initiator methionine codon at base 316, located in the context of an optimal translation initiation sequence. An in-frame stop codon is located 240 bases upstream from this site. The protein product of IT15 is predicted to be a 348 kDa protein containing 3,144 amino acids. Although the first Met codon in the long open reading frame has been chosen as the probably initiator codon, we cannot exclude that translation does not actually begin at a more 3' Met codon, producing a smaller protein. Example 2 Polymorphic Variation of the (CAG) n Trinucleotide Repeat Near its 5' end, the IT15 sequence contains 21 copies of the triplet CAG, encoding glutamine (Figure 5). When this sequence was compared with genomic sequences that are known to surround simple sequence repeats (SSRs) in 4p16.3, it was found that normal cosmid L191F1 had 18 copies of the triplet indicating that the (CAG) n repeat is polymorphic (Figure 5). Primers from the genomic sequence flanking the repeat were chosen to establish a PCR assay for this variation. In the normal population, this SSR polymorphism displays at least 17 discrete alleles (Table 1) ranging from about 11 to about 34 repeat units. Ninety-eight percent of the 173 normal chromosomes tested contained repeat lengths between 11 and 24 repeats. Two chromosomes were detected in the 25-30 repeat range and 2 normal chromosomes had 33 and 34 repeats respectively. The overall heterozygosity on normal chromosome was 80%. Based on sequence analysis of three clones, it appears that the variation is based entirely on the (CAG) n , but the potential for variation of the smaller downstream (CCG) 7 which is also included in the PCR product, is also present. Example 3 Instability of the Trinucleotide Repeat on HD chromosomes Sequence analysis of cosmid GUS72-2130, derived from a chromosome with the major HD haplotype (see below), revealed 48 copies of the trinucleotide repeat, far greater than the largest normal allele (Figure 5). When the PCR assay was applied to HD chromosomes, a pattern strikingly different from the normal variation was observed. HD heterozygotes contained one discrete allelic product in the normal size range, and one PCR product of much larger size, suggesting that the (CAG) n repeat on HD chromosomes is expanded relative to normal chromosomes. Figure 6 shows the patterns observed when the PCR assay was performed on lymphoblast DNA from a selected nuclear family in a large Venezuelan HD kindred. In this family, DNA marker analysis has shown previously that the HD chromosome was transmitted from the father (lane 2) to seven children (lanes 3, 5, 6, 7, 8, 10 and 11). The three normal chromosomes present in this mating yielded a PCR product in the normal size range (AN1, AN2, AN3) that was inherited in a Mendelian fashion. The HD chromosome in the father yielded a diffuse, "fuzzy"-appearing PCR product slightly smaller than the 48 repeat product of the non-Venezuelan HD cosmid. Except for the DNA in lane 5 which did not PCR amplify and in lane 11 which displayed only a single normal allele, each of the affected children's DNAs yielded a fuzzy PCR product of a different size (AE), indicating instability of the HD chromosome (CAG) n repeat. Lane 6 contained an HD -specific product slightly smaller than or equal to that of the father's DNA. Lanes 3, 7, 10 and 8, respectively, contained HD- specific PCR products of progressively larger size. The absence of an HD -specific PCR product in lane 11 suggested that this child's DNA possessed a (CAG) n repeat that was too long to amplify efficiently. This was verified by Southern blot analysis in which the expanded HD allele was easily detected and estimated to contain up to 100 copies of the repeat. Notably, this child had juvenile onset of HD at the very early age of 2 years. The onset of HD in the father was in his early 40s, typical of most adult HD patients in this population. The onset ages of children represented by lanes 3, 7, 10 and 8 were 26, 25, 14 and 11 years, respectively, suggesting a rough correlation between age at onset of HD and the length of the (CAG) n repeat on the HD chromosome. In keeping with this trend, the offspring represented in lane 6 with the fewest repeats remained asymptomatic when last examined at age of 30. Figure 7 shows PCR analysis for a second sibship from the Venezuelan pedigree in which both parents are HD heterozygotes carrying the same HD chromosome based on DNA marker studies. Several of the offspring are HD homozygotes (lanes 6+7, 10+11, 13+14, 17+18, 23+24) as reported previously (Wexler et al., Nature 326 :194-197 (1987)). Each parent's DNA contained one allele in the normal range (AN1, AN2) which was transmitted in a Mendelian fashion. The HD -specific products (AE) from the DNA of both parents and children were all much larger than the normal allelic products and also showed extensive variation in mean size. A neurologic diagnosis for the offspring in this pedigree was not provided to maintain the blind status of investigators involved in the ongoing Venezuela HD project, although age of onset again appears to parallel repeat length. Paired samples under many of the individual symbols represent independent lymphoblast lines initiated at least one year apart. The variance between paired samples was not as great as between the different individuals, suggesting that the major differences in size of the PCR products resulted from meiotic transmission. Of special note is the result obtained in lanes 13 and 14. This HD homozygote's DNA yielded one PCR product larger and one smaller than the HD -specific PCR products of both parents. To date, we have tested 75 independent HD families, representing all different reported in MacDonald et al., Nature Genet. 1 :99-103 (1992)) and a wide range of ethnic backgrounds. In all 75 cases, a PCR product larger than the normal size range was produced from the HD chromosome. The sizes of the HD -specific products ranged from 42 repeat copies to more than 66 copies, with a few individuals failing to yield a product because of the extreme length of the repeat. In these cases, Southern blot analysis revealed an increase in the length of an EcoRI fragment with the largest allele approximating 100 copies of the repeat. Figure 8 shows the variation detected in members of an American family of Irish ancestry in which the major HD haplotype is segregating. Cosmid GUS72-2130 was cloned from the HD homozygous individual whose DNA was amplified in lane 2. As was observed in the Venezuelan HD pedigree (Figures 6 and 7), which segregates the disorder with a different 4p16.3 haplotype, the HD -specific PCR products for this family display considerable size variation. Example 4 New Mutations to HD The mutation rate in HD has been reported to be very low. To test whether the expansion of the (CAG) n repeat is the mechanism by which new HD mutations occur, two pedigrees with sporadic cases of HD have been examined in which intensive searching failed to reveal a family history of the disorder. In these cases, pedigree information sufficient to identify the same chromosomes in both the affected individual and unaffective relatives was gathered. Figures 9 and 10 show the results of PCR analysis of the (CAG) n repeat in these families. The chromosomes in each family were assigned an arbitrary number based on typing for a large number of RFLP and SSR markers in 4p16.3 defining distinct haplotypes and the presumed HD chromosome is starred. In family #1, HD first appeared in individual II-3 who transmitted the disorder to III-1 along with chromosome 3 * . This same chromosome was present in II-2, an elderly unaffected individual. PCR analysis revealed that chromosome 3* from II-2 produced a PCR product at the extreme high end of the normal range (about 36 CAG copies). However, the (CAG) n repeat on the same chromosome in II-3 and III-1 had undergone sequential expansions to about 44 and about 46 copies, respectively. A similar result was obtained in Family #2, where the presumed HD mutant III-2 had a considerably expanded repeat relative to the same chromosome in II-1 and III-1 (about 49 vs. about 33 CAG copies). In both family #1 and family #2, the ultimate HD chromosome displays the marker haplotype characteristic of 1/3 of all HD chromosomes, suggesting that this haplotype may be predisposed to undergoing repeat expansion. Discussion The discovery of an expanded, unstable trinucleotide repeat on HD chromosomes within the IT15 gene is the basis for utilizing this gene as the HD gene of the invention. These results are consistent with the interpretation that HD constitutes the latest example of a mutational mechanism that may prove quite common in human genetic disease. Elongation of a trinucleotide repeat sequence has been implicated previously as the cause of three quite different human disorders, the fragile X syndrome, myotonic dystrophy and spino-bulbar muscular atrophy. The initial observations of repeat expansion in HD indicate that this phenomenon shares features in common with each of these disorders. In the fragile X syndrome, expression of a constellation of symptoms that includes mental retardation and a fragile site at Xq27.3 is associated with expansion of a (CGG) n repeat thought to be in the 5' untranslated region of the FMR1 gene (Fu et al., Cell 67 :1047-1058 (1991); Kremer et al., Science 252 :1711-1714 (1991); Verkerk et al., Cell 65 :904-914 (1991)). In myotonic dystrophy, a dominant disorder involving muscle weakness with myotonia that typically present in early adulthood, the unstable trinucleotide repeat, (CTG) n , is located in the 3' untranslated region of the mysotonin protein kinase gene (Aslanidis et al., Nature 355 :548-551 (1992); Brook et al., Cell 68 :799-808 (1992); Buxton et al., Nature 355:547-548 (1992); Fu et al., Science 255 :1256-1259 (1992); Harley et al., Lancet 339 :1125-1128 (1992); Mahadevan et al., Science 255 :1253-1255 (1992)). The unstable (CAG) n repeat in HD may be within the coding sequence of the IT15 gene, a feature shared with spino-bulbar muscular atrophy, an X-linked recessive adult-onset disorder of the motor neurons caused by expansion of a (CAG) n repeat in the coding sequence of the androgen receptor gene (LaSpada et al., Nature 352 :77-79 (1991)). The repeat length in both the fragile X syndrome and myotonic dystrophy tends to increase in successive generations, sometimes quite dramatically. Occasionally, decreases in the average repeat length are observed (Fu et al., Science 255 :1256-1259 (1992); Yu et al., Am. J. Hum . Genet. 50 :968-980 (1992); Bruner et al., N. Engl. J. Med .:476-480 (1993)). The HD trinucleotide repeat is also unstable, usually expanding when transmitted to the next generation, but contracting on occasion. In HD, as in the other disorders, change in copy number occurs in the absence of recombination. Compared with the fragile X syndrome, myotonic dystrophy, and HD, the instability of the disease allele in spino-bulbar muscular atrophy is more limited, and dramatic expansions of repeat length have not been seen (Biancalana et al., Hum. Mol. Genet. 1 :255-258 (1992)). Expansion of the repeat length in myotonic dystrophy is associated with a particular chromosomal haplotype, suggesting the existence of a primordial predisposing mutation (Harley et al., Am. J. Hum. Genet. 49 :68-75 (1991); Harley et al., Nature 355 :545-546 (1992); Ashizawa, Lancet 338 :642-643 (1991); and Epstein (1991)). In the fragile X syndrome, there may be a limited number of ancestral mutations that predispose to increases in trinucleotide repeat number (Richards et al., Nature Genet. 1 :257-260 (1992); Oudet et al., Am. J. Hum. Genet. 52 :297-304 (1993)). The linkage disequilibrium analysis used to identify IT15 indicates that there are several haplotypes associated with HD, but that at least 1/3 of HD chromosomes are ancestrally related (MacDonald et al., Nature Genet. 1 :99-103 (1992)). These data, combined with the reported low rate of new mutation to HD (Harper, J. Med. Genet. 89 :365-376 (1992)), suggest that expansion of the trinucleotide repeat may only occur on select chromosomes. The analysis of two families presented herein, in which new mutation was supposed to have occurred, is consistent with the view that there may be particular normal chromosomes that have the capacity to undergo expansion of the repeat into the HD range. In each of these families, a chromosome with a (CAG) n repeat length in the upper end of the normal range was segregating on a chromosome whose 4p16.3 haplotype matched the most common haplotype seen on HD chromosomes and the clinical appearance of HD in these two cases was associated with expansion of the trinucleotide repeat. The recent application of haplotype analysis to explore the linkage disequilibrium on HD chromosomes pointed to a portion of a 2.2 Mb candidate region defined by the majority of recombination events described in HD pedigrees (MacDonald et al., Nature Genet 1 :99-103 (1992)). Previously, the search for the gene was confounded by three matings in which the genetic inheritance pattern was inconsistent with the remainder of the family (MacDonald et al., Neuron 3 :183-190 (1989b); Prichard et al., Am. J. Hum. Genet. 50 :1218-1230 (1992)). These matings produced apparently affected HD individuals despite the inheritance of only normal alleles for markers throughout 4p16.3, effectively excluding inheritance of the HD chromosome present in the rest of the pedigree. Using PCR assay disclosed above, each of these families was tested and it was determined that like other HD kindreds, an expanded allele segregates with HD in affected individuals of all three pedigrees. However, an expanded allele was not present in those specific individuals with the inconsistent 4p16.3 genotypes. Instead, these individuals displayed the normal alleles expected based on analysis of other markers in 4p16.3. It is conceivable that these inconsistent individuals do not, in fact, have HD, but some other disorder. Alternatively, they might represent genetic mosaics in which the HD allele is more heavily represented and/or more expanded in brain tissue than in the lymphoblast DNA used for genotyping. The capacity to monitor directly the size of the trinucleotide repeat in individuals "at risk" for HD provides significant advantages over current methods, eliminating the need for complicated linkage analyses, facilitating genetic counseling, and extending the applicability of presymptomatic and prenatal diagnosis to "at risk" individuals with no living affected relatives. however, it is of the utmost importance that the current internationally accepted guidelines and counseling protocols for testing those "at risk" continue to be observed, and that samples from unaffected relatives should not be tested inadvertently or without full consent. In the series of patients examined in this study, there is an apparent correlation between repeat length and age of onset of the disease, reminiscent of that reported in myotonic dystrophy (Harley et al., Lancet 339 :1125-1128 (1992); Tsilfidis et al., Nature Genet. 1 :192-195 (1992)). The largest HD trinucleotide repeat segments were found in juvenile onset cases, where there is a known preponderance of male transmission (Merrit et al., Excerpta Medica, Amsterdam, pp. 645-650 (1969)). The expression of fragile X syndrome is associated with direct inactivation of the FMR1 gene (Pierretti et al., Cell 66 :817-822 (1991); DeBoulle et al., Nature Genet. 3:31-35 (1993)). The recessive inheritance pattern of spino-bulbar muscular atrophy suggests that in this disorder, an inactive gene product is produced. In myotonic dystrophy, the manner in which repeat expansion leads to the dominant disease phenotype is unknown. There are numerous possibilities for the mechanism of pathogenesis of the expanded trinucleotide repeat in HD. Without intending to be held to this theory, nevertheless notice can be taken that since Wolf-Hirschhorn patients hemizygous for 4p16.3 do not display features of HD, and IT15 mRNA is present in HD homozygotes, the expanded trinucleotide repeat does not cause simple inactivation of the gene containing it. The observation that the phenotype of HD is completely dominant, since homozygotes for the disease allele do not differ clinically from heterozygotes, has suggested that HD results from a gain of function mutation, in which either the mRNA product or the protein product of the disease allele would have some new property, or be expressed inappropriately (Wexler et al., Nature 326 :194-197 (1987); Myers et al., Am. J. Hum. Genet. 45 :615-618 (1989)). If the expanded trinucleotide repeat were translated, the consequences on the protein product would be dramatic, increasing the length of the poly-glutamine stretch near the N-terminus. It is possible, however, that despite the presence of an upstream Met codon, the normal translational start occurs 3' to the (CAG) n repeat and there is no poly-glutamine stretch in the protein product. In this case, the repeat would be in the 5' untranslated region and might be expected to have its dominant effect at the mRNA level. The presence of an expanded repeat might directly alter regulation, localization, stability or translatability of the mRNA containing it, and could indirectly affect its counterpart from the normal allele in HD heterozygotes. Other conceivable scenarios are that the presence of an expanded repeat might alter the effective translation start site for the HD transcript, thereby truncating the protein, or alter the transcription start site for the IT15 gene, disrupting control of mRNA expression. Finally, although the repeat is located within the IT15 transcript, the possibility that it leads to HD by virtue of an action on the expression of an adjacent gene cannot be excluded. Despite this final caveat, it is consistent with the above results and most likely that the trinucleotide repeat expansion causes HD by its effect, either at the mRNA or protein level, on the expression and/or structure of the protein product of the IT15 gene, which has been named huntingtin. Outside of the region of the triplet repeat, the IT15 DNA sequence detected no significant similarity to any previously reported gene in the GenBank database. Except for the stretches of glutamine and proline near the N-terminus, the amino acid sequence displayed no similarity to known proteins, providing no conspicuous clues to huntingtin's function. The poly-glutamine and poly-proline region near the N-terminus detect similarity with a large number of proteins which also contain long stretches of these amino acids. It is difficult to assess the significance of such similarities, although it is notable that many of these are DNA binding proteins and that huntingtin does have a single leucine zipper motiff at residue 1,443. Huntingtin appears to be widely expressed, and yet cell death in HD is confined to specific neurons in particular regions of the brain. COMPARISON OF HD AND NORMAL REPEAT SIZES RANGE OF ALLELE SIZES (#REPEATS) NORMAL CHROMOSOMES NUMBER AND FREQUENCY HD CHROMOSOMES NUMBER AND FREQUENCY ≥ 48 0 0 44 0.59 42-47 0 0 30 0.41 30-41 2 0.01 0 0 25-30 2 0.01 0 0 ≤ 24 169 0.98 0 0 TOTAL 173 1.00 74 1.0 Example 5 Distribution of Trinucleotide Repeat Lengths on Normal and HD Chromosomes The number of copies of the HD triplet repeat has been examined in a total of 425 HD chromosomes from 150 independent families and compared with the copy number of the HD triplet repeat of 545 normal chromosomes. The results are displayed in Figure 11. Two non-overlapping distributions of repeat length were observed, wherein the upper end of the normal range and the lower end of the HD range were separated by 3 repeat units. The normal chromosomes displayed 24 alleles producing PCR products ranging from 11 to 34 repeat units, with a median of 19 units (mean 19.71, s.d. 3.21). The HD chromosomes yielded 54 discrete PCR products corresponding to repeat lengths of 37 to 86 units, with a median of 45 units (mean 46.42, s.d. 6.68). Of the HD chromosomes, 134 and 161 were known to be maternally or paternally-derived, respectively. To investigate whether the sex of the transmitting parent might influence the distribution of repeat lengths, these two sets of chromosomes were plotted separately in Figure 12. The maternally-derived chromosomes displayed repeat lengths ranging from 37 to 73 units, with a median of 44 (mean 44.93, s.d. 5.14). The paternally-derived chromosomes had 37 to 86 copies of the repeat unit, with a median of 48 units (mean 49.14, s.d. 8.27). However, a higher proportion of the paternally-derived HD chromosomes had repeat lengths greater than 55 units (16% vs. 2%), suggesting the possibility of a differential effect of paternal versus maternal transmission. The data set used excluded chromosomes from a few clinically diagnosed individuals who have previously been shown not to have inherited the HD chromosome by DNA marker linkage studies (MacDonald, M.E., et al ., Neuron 3 :183-190 (1989); Pritchard, C., et al., Am. J. Hum. Genet. 50 :1218-1230 (1992)). These individuals have repeat lengths well within the normal range. Their disease manifestations have not been explained, and they may represent phenocopies of HD. Regardless of the mechanism involved, the occurrence at low frequency of such individuals within known HD families must be considered if diagnostic conclusions are based solely on repeat length. The control data set also excludes a number of chromosomes from phenotypically normal individuals who are related to "spontaneous" cases of HD or "new mutations". Chromosomes from these individuals who are not clinically affected and have no family history of the disorder cannot be designated as HD. However, these chromosomes cannot be classified as unambiguously normal because they are essentially the same chromosome as that of an affected relative, the diagnosed "spontaneous" HD proband, except with respect to repeat length. The lengths of repeat found on these ambiguous chromosomes (34-38 units) span the gap between the control and HD distributions, confounding a decision on the status of any individual with a repeat in the high normal to low HD range. Example 6 Instability of the Trinucleotide Repeat The data in Figure 11 combine repeat lengths from 150 different HD families representing many potentially independent origins of the defect. To examine the variation in repeat lengths on sets of HD chromosomes known to descend from a common founder, the data from three large HD kindreds (Gusella, J.F., et al., Nature 306 :234-238 (1983); Wexler, N.S., et al., Nature 326 :194-197 (1987); Folstein, S.E., et al., Science 229 :776-779 (1985)) with different 4p16.3 haplotypes (MacDonald, M.E., et al., Nature Genet. 1 :99-103 (1992)), typed for 75, 25 and 35 individuals, respectively, were separated. Despite the single origin of the founder HD chromosome within each pedigree, members of the separate pedigrees display a wide range of repeat lengths (Figure 13). This instability of the HD chromosome repeat is most prominent in members of a large Venezuelan HD kindred (panel A) In which the common HD ancestor has produced 10 generations of descendants, numbering over 13,000 individuals. The distribution of repeat lengths in this sampling of the Venezuelan pedigree (median 46, mean 48.26, s.d. 9.3) is not significantly different from that of the larger sample of HD chromosomes from all families. Panels B and C display results for two extended families in which HD was introduced more recently than in the Venezuelan kindred. These families have been reported to exhibit different age of onset distributions and varied phenotypic features of HD (Folstein, S.E., et al., Science 229 :776-779 (1985)). Both revealed extensive repeat length variation, with a median of 41 and 49 repeat units, respectively. The distribution of repeat lengths in the members of the family in Panel B was significantly different from the distribution of all HD chromosome repeat lengths (p<0.0001), with a smaller mean of 42.04 repeat units (s.d. 2.82). The repeat distribution from HD chromosomes of Panel C was also significantly different from the total data set (p<0.004), but with a higher mean of 49.80(s.d. 5.86). Example 7 Parental Source Effects on Repeat Length Variation For 62 HD chromosomes in Figure 11, the length of the trinucleotide repeat also could be examined on the corresponding parental HD chromosome. In 20 of 25 maternal transmissions, and in 31 of 37 paternal transmissions, the repeat length was altered, indicating considerable instability. A similar phenomenon was not observed for normal chromosomes, where more than 500 meiotic transmissions revealed no changes in repeat length, although the very existence of such a large number of normal alleles suggests at least a low degree. of instability. Figure 14 shows the relationship between the repeat lengths on the HD chromosomes in the affected parent and corresponding progeny. For the 20 maternally-inherited chromosomes on which the repeat length was altered, 13 changes were increases in length and 7 were decreases. Both increases and decreases involved changes of less than 5 repeat units and the overall correlation between the mother's repeat length and that of her child was r=0.95 (p<0.0001). The average change in repeat length in the 25 maternal transmissions was an increase of 0.4 repeats. On paternally-derived chromosomes, the 31 transmissions in which the repeat length changes comprised 26 length increases and 5 length decreases. Although the decreases in size were only slightly smaller than those observed on maternally-derived chromosomes, ranging from 1 to 3 repeat units, the increases were often dramatically larger. Thus, the correlation of the repeat length in the father with that of his offspring was only r=0.35 (p<0.04). The average change in the 37 paternal transmissions was an increase of 9 repeat units. The maximum length increase observed through paternal transmission was 41 repeat units, a near doubling of the parental repeat. For both male and female transmissions, there was no correlation between the size of the parental repeat and either the magnitude or frequency of changes. To determine whether the variation in the length of the repeat observed through male transmission of HD chromosomes is reflected in the male germ cells, we amplified the repeat from sperm DNA and from DNA of the corresponding lymphoblast from 5 HD gene carriers. The results, shown in Figure 15, reveal striking differences between the lymphoblast and sperm DNA for the HD chromosome repeat, but not for the repeat on the normal chromosome. All the sperm donors are members of the Venezuelan HD family and range in age from 24 to 30 years. Individuals 1 and 2 are siblings with HD chromosome repeat lengths based on lymphoblast DNA of 45 and 52, respectively. Individuals 3 and 4 are also siblings, with HD repeat lengths of 46 and 49, respectively. Individual 5, from a different sibship than either of the other two pairs, has an HD repeat of 52 copies. In all 5 cases, the PCR amplification of sperm DNA and lymphoblast DNA yielded identical products from the normal chromosome. However, in comparison with lymphoblast DNA, the HD gene from sperm DNA yielded a diffuse array of products. In 3 of the 5 cases (2,4 and 5), the diffuse array spread to much larger allelic products than the corresponding lymphoblast product. Subject 2 showed the greatest range of expansion, with the sperm DNA product extending to over 80 repeat units. Interestingly, the 3 individuals displaying the greatest variation have the longest repeats and are currently symptomatic. The other two donors have shorter repeat lengths in the HD range, and remain at risk at this time. The striking difference in the high repeat length range (>55) between HD chromosomes transmitted from the father and those transmitted from the mother indicated a potential parental source effect. When this was examined directly, the HD chromosome repeat length changed in about 85% of transmissions. Most changes involved a fluctuation of only a few repeat units, with larger increases occurring only in male transmissions. The greater size increases in male transmission appear to be caused by particular instability of the HD trinucleotide repeat during male gametogenesis, based on the amplification of the repeat from sperm DNA. Example 8 Relationship between Repeat Length and Age of Onset Increased repeat length might correlate with a reduced age of onset of HD. Accordingly, age of onset data was determined for 234 of the individuals represented in Figure 11. Figure 16 displays the repeat lengths found on the HD and normal chromosomes of these individuals relative to their age of onset. Indeed, age of onset is inversely correlated with the HD repeat length. A Pearson correlation coefficient of r=-.75, p <0.0001 was obtained assuming a linear relationship between age of onset and repeat length. When a polynomial function was used, a better fit was obtained (R 2 =0.61, F=121.45), suggesting a higher order association between age of onset and repeat length. There is considerable variation in the age of onset associated with any specific number of repeat units, particularly for trinucleotide repeats in the 37-52 unit zone (88% of HD chromosomes) where onset ranged from 15 to 75 years. In this range, a linear relationship between age of onset and repeat length provided as good a fit as a higher order relationship. The 95% confidence interval surrounding the predicted regression line was estimated at ±18 years. In the 37 to 52 unit range, the association of repeat length to onset age is only half as strong as in the overall distribution (r=-0.40, p<.0001), indicating that much of the predictive power is contributed by repeats longer than 52 units. In this increased range, onset is likely to be very young and consequently not relevant to most persons seeking testing. For the 178 cases in the 37-52 repeat unit range for which it was possible to subdivide the data set based on parental origin of the HD gene, multivariate regression analysis suggested a significant effect of parental origin on age of onset (p < 0.05) independent of repeat length in this range. HD gene carriers from maternal transmissions had an average age of onset two years later than those from paternal transmissions. In both univariate and multivariate analyses, no association between age of onset and the repeat length on the normal chromosome was detected, either in the total data set, or when it was subdivided into chromosomes of maternal or paternal origin. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: THE GENERAL HOSPITAL CORPORATION Fruit Street Boston, Massachusetts 02114 United States of America (ii) TITLE OF INVENTION: Huntingtin DNA, Protein And Uses Thereof (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS: (A) KILBURN & STRODE (B) 30 JOHN STREET (C) LONDON (D) GREAT BRITAIN (E) WC1N 2DD (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) 7th March 1994 (vii)PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/085,000 (B) FILING DATE: 01 JULY 1993 (vii)PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/027,498 (B) FILING DATE: 05 MARCH 1993 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10366 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 316..9748 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3144 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Claims: An isolated, purified or recombinant huntingtin polypeptide comprising the amino acid sequence shown in SEQ ID NO:6. An isolated, purified or recombinant nucleic acid molecule comprising a huntingtin nucleic acid molecule encoding a huntingtin polypeptide according to claim 1, or its complementary strand. A nucleic acid molecule according to claim 2, comprising the nucleic acid shown in SEQ ID NO:5. A nucleic acid molecule according to claim 2 or claim 3, comprising a transcriptional control region operably linked to said huntingtin nucleic acid molecule. A vector comprising a nucleic acid molecule according to any of claims 2 to 4. A vector according to claim 5, wherein the nucleic acid molecule is operably linked to transcriptional and/or translational expression signals. A host cell transformed or transfected with a vector according to claim 5 or claim 6. An antibody specific for huntingtin polypeptide as claimed in claim 1. A hybridoma which produces an antibody according to claim 8. A method of detecting the presence of, or predisposition to develop, Huntington's disease in a subject, the method comprising (a) evaluating the characteristics of huntingtin nucleic acid in a sample from the subject, wherein the evaluation comprises detecting the huntingtin (CAG) n region shown in SEQ ID NO:5 in the sample; and (b) comparing the characteristics found in (a) with a similar analysis from an individual with no family history of Huntington's disease, where the nucleic acid has from 11 to 34 (CAG) repeats, the presence of, or predisposition to develop, Huntington's disease being indicated if those characteristics in the huntingtin (CAG) n region differ. A method according to claim 10, wherein the characteristics of huntingtin nucleic acid are evaluated by Southern blot, northern blot, or polymerase chain reaction analysis. The use of: (a) a nucleic acid molecule according to claim 2, 3 or 4 or a vector according to claim 5 or claim 6; (b) a polypeptide according to claim 1; and/or (c) a host cell according to claim 7 in the preparation of a medicament. The use according to claim 12, wherein the medicament is for treating, delaying or preventing a neurodegenerative disorder. The use according to claim 12 or claim 13, wherein the medicament is for gene therapy. The use according to claim 12, 13 or 14, wherein the medicament is for treating, preventing or delaying Huntingdon's disease. The use according to any of claims 12 to 15 wherein the nucleic acid has from 11 to 34 (CAG) repeats and/or the polypeptide has from 11 to 34 Gln repeats, said repeats being consecutive. A diagnostic and/or immunoassay kit comprising at least one container and; (a) a nucleic acid molecule according to claim 2, 3 or 4, optionally labelled; or (b) an antibody according to claim 8, optionally labelled. A pharmaceutical composition comprising: (a) a nucleic acid molecule according to claim 2, 3 or 4 or a vector according to claim 5 or claim 6; (b) a polypeptide according to claim 1; and/or (c) a host cell according to claim 7 in admixture with pharmaceutically acceptable carrier. A process for the preparation of a polypeptide according to claim 1, the process comprising culturing a host cell according to claim 7 under conditions whereby the polypeptide is expressed, and purifying or isolating the polypeptide.

Inventors: AMBROSE CHRISTINE M, DUYAO MABEL P, GUSELLA JAMES F, MACDONALD MARCY E, AMBROSE, CHRISTINE M., DUYAO, MABEL P., GUSELLA, JAMES F., MACDONALD, MARCY E.
Applicants: GEN HOSPITAL CORP, THE GENERAL HOSPITAL CORPORATION
Application year: 1994
Main classification: C12N15
IPC codes: C12Q1, A61K38, A61P21, C07K1, C07K14, C07K16, G01N33, C12P21, C12N15